<DOC>
	<DOCNO>NCT03032913</DOCNO>
	<brief_summary>The proposal aim determine whether liquid biopsy approach valid diagnosis pancreatic cancer . Step1 test 3 CTC isolation method analyse flow cytometry presence onco-exosomes culture medium pancreatic cell line . Step 2 examine diagnostic accuracy blood tumor element diagnosis cancer patient PDAC suspicion recent diagnosis value disease monitoring .</brief_summary>
	<brief_title>Diagnostic Accuracy Circulating Tumor Cells ( CTCs ) Onco-exosome Quantification Diagnosis Pancreatic Cancer - PANC-CTC</brief_title>
	<detailed_description>Pancreatic ductal adenocarcinoma ( PDAC ) incidence increase high rate past year ( +4.7 % per year 2005 2012 , source InfoCancer 2013 ) . No cure currently available deadly disease , overall survival &lt; 5 % . Survival reach 20 % surgery possible , give best chance patient . If patient present locally advance disease , crucial quickly establish resectability avoid unneeded even deleterious surgery patient metastatic stage . It also important increase rate true R0 resection effective preoperative therapy . However , cancer suspect , neoadjuvant chemotherapy often delay mandatory histologic proof difficult make non-informative biopsy . It necessary find new marker help rapid diagnosis could allow neoadjuvant therapy surgery anatomo-pathologic proof available . New development field liquid biopsy hold great promise provide valuable information diagnosis assistance . The project run two step . First , several method compare tumor cell recovery cell spike blood non-cancer patient pancreatic cell line onco-exosomes characterize flow cytometry . Second best method use detect enumerate CTCs 20 PDAC patient 20 non-cancer patient . In parallel GPC1+ exosomes patient ' plasma quantify . Diagnosis accuracy establish compare . Correlations circulate tumor element presence clinical biological parameter evaluate time diagnosis . Patient clinical outcome assess accord initial circulating element quantification .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Patient inform consent Patient health care coverage Group PDAC patient : Patient resectable lesion suspicion recent diagnosis PDAC recruit surgery department Group noncancer patient : Patients surgery department without cancer lesion , Patients intestine inflammatory disease , Patients gastric bypass sleeve gastrectomy procedure Patients &lt; 18 tutelage Patient recent chemotherapy radiotherapy Pregnant lactate woman Patient negative noninformative biopsy Patient technically unserectable disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Cancer</keyword>
	<keyword>Circulating tumor cell ( CTC )</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Ductal</keyword>
	<keyword>Exosome</keyword>
</DOC>